Literature DB >> 12617333

Relationship between elevated serum troponin values in end-stage renal disease patients and abnormal isotopic cardiac scans following stress.

George A Porter1, Theadore L Norton, Jessie Lindsley, Jeffrey S Stevens, David S Phillips, William M Bennett.   

Abstract

One hundred asymptomatic high-risk renal transplant candidates were screened for asymptomatic coronary artery disease using stress cardiac isotopic imaging. The cardiac markers, serum cTnT, cTnI, and CKMB, were collected pre and post stress testing. Of the 99 patients whose cardiac scans were technically satisfactory, 32 were normal, 49 had a definite imaging abnormality and the scan was indeterminate in the remaining 18 patients. Based on these results, patients were stratified into either normal, indeterminate or abnormal scan groups. They then were analyzed to detect any correlations between cardiac perfusion defects and either elevated pre-stress cardiac markers or consistent changes 24h after stress testing. While the mean pre-stress serum values for both cardiac troponin T (0.117 +/- 0.12 microgram/L) and cardiac troponin I (0.235 +/- 0.89 microgram/L) were increased in the abnormal cardiac scan group, only the cTnT value proved to differ significantly from the normal group (p < 0.01). For the indeterminate group neither marker was different from the normal scan group. Only an elevated serum cTnT > 0.1 microgram/L (OR 3.042, p = 0.030) proved to discriminate an abnormal scan in this population. It is concluded that the increase in pre-stress serum cTnT encountered in patients with chronic renal failure, with or without evidence of overt, symptomatic coronary artery disease, may represent a combination of subclinical myocardial damage and a prolonged half-life of the marker in the serum. Because of the frequency of elevated serum concentrations of cTnT and, to a lesser degree cTnI, the physician should exercise caution when interpreting a single elevated Troponin value during the evaluation of chest pain in patients with end-stage renal disease. A cTnT > 0.1 microgram/L increases the likelihood of finding significant coronary artery disease three fold in high-risk ESRD patients being evaluated for renal transplantation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12617333     DOI: 10.1081/jdi-120017468

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  7 in total

Review 1.  Cardiac testing for coronary artery disease in potential kidney transplant recipients.

Authors:  Louis W Wang; Magid A Fahim; Andrew Hayen; Ruth L Mitchell; Laura Baines; Stephen Lord; Jonathan C Craig; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  A review of troponins in ischemic heart disease and other conditions.

Authors:  Nedaa Skeik; Deevia Chandrakant Patel
Journal:  Int J Angiol       Date:  2007

3.  The role of radionuclide myocardial perfusion imaging for asymptomatic individuals.

Authors:  Robert C Hendel; Brian G Abbott; Timothy M Bateman; Ron Blankstein; Dennis A Calnon; Jeffrey A Leppo; Jamshid Maddahi; Matthew M Schumaecker; Leslee J Shaw; R Parker Ward; David G Wolinsky
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

Review 4.  Cardiac enzymes, renal failure and renal transplantation.

Authors:  Huseyin Bozbas; Aylin Yildirir; Haldun Muderrisoglu
Journal:  Clin Med Res       Date:  2006-03

Review 5.  Troponin: the biomarker of choice for the detection of cardiac injury.

Authors:  Luciano Babuin; Allan S Jaffe
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

6.  Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T.

Authors:  R Sharma; D C Gaze; D Pellerin; R L Mehta; H Gregson; C P Streather; P O Collinson; S J D Brecker
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

7.  Association of maximal stress ergometry performance with troponin T and abdominal aortic calcification score in advanced chronic kidney disease.

Authors:  Roosa Lankinen; Markus Hakamäki; Kaj Metsärinne; Niina Koivuviita; Jussi P Pärkkä; Maria Saarenhovi; Tapio Hellman; Mikko J Järvisalo
Journal:  BMC Nephrol       Date:  2021-02-04       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.